KETOPROFEN-E TABLET (ENTERIC-COATED)

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

KETOPROFEN

Disponibbli minn:

AA PHARMA INC

Kodiċi ATC:

M01AE03

INN (Isem Internazzjonali):

KETOPROFEN

Dożaġġ:

100MG

Għamla farmaċewtika:

TABLET (ENTERIC-COATED)

Kompożizzjoni:

KETOPROFEN 100MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100/500/1000

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0110497002; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2011-02-16

Karatteristiċi tal-prodott

_Pr_
_KETOPROFEN, _
_Pr_
_KETOPROFEN-E and _
_Pr_
_KETOPROFEN SR (Ketoprofen)_
_ _
_Page 1 of 49_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
KETOPROFEN
Ketoprofen Capsules BP
Capsule, 50 mg, for oral use
Pr
KETOPROFEN-E
Ketoprofen Enteric-coated Tablets
Tablet, 50 mg and 100 mg, for oral use
Pr
KETOPROFEN SR
Ketoprofen Sustained-release Tablets
Tablet, 200 mg, for oral use
Non-Steroidal Anti-inflammatory Drug (NSAID)
AA PHARMA INC.
1165 Creditstone Road, Unit #1
Vaughan, Ontario
L4K 4N7
Date of Initial Authorization:
DEC 31, 1989
Date of Revision:
MAY 10, 2022
Submission Control Number: 258038
_ _
_Pr_
_KETOPROFEN, _
_Pr_
_KETOPROFEN-E and _
_Pr_
_KETOPROFEN SR (Ketoprofen)_
_ _
_Page 2 of 49_
RECENT MAJOR LABEL CHANGES
1 Indications
05/2022
2 Contraindications
05/2022
3 Serious Warnings and Precautions Box
05/2022
4 Dosage and Administration, 4.1 Dosing Considerations
05/2022
4 Dosage and Administration, 4.2 Recommended Dose and
Dosage Adjustment
05/2022
4 Dosage and Administration, 4.4 Administration
05/2022
7 Warnings and Precautions
05/2022
7 Warnings and Precautions, 7.1.1 Pregnant Women
05/2022
7 Warnings and Precautions, 7.1.2 Breast-feeding
05/2022
7 Warnings and Precautions, 7.1.4 Geriatrics
05/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES..............................................................................................2
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
................................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics........................................................